×
0 0 0 0 0 -0.000411861614497593 -0.000411861614497593 -0.000411861614497593
Stockreport

Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

AKCEA THERAPEUTICS (AKCA)  More Company Research Source: GlobeNewswire
Last akcea therapeutics earnings: 8/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion of a new study to assess the burden of people living with Familial Chylomicronemia Syndrome (FCS) and its impact on their daily lives. Results from the study known as Re-FOCUS were published on June 11, 2018 in the peer-reviewed journal Expert Review of Cardiovascular Therapy. Twenty-two people with FCS participated in the Re-FOCUS survey. They were asked to assess the number and severity of a range of symptoms and daily life measures affected by FCS. The web-based global study was conducted among people with FCS treated with volanesorsen, Akcea’s investigational therapy currently under regulatory review in the US, EU and Canada. “FCS is an ultra-rare disease that has not been widely studied. This landmark study represents an [Read more]

IMPACT SNAPSHOT EVENT TIME: AKCA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AKCA alerts
from News Quantified
Opt-in for
AKCA alerts

from News Quantified
Opt-in for
AKCA alerts

from News Quantified